Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca

When it comes to PARP inhibitor Rubraca, Clovis Oncology is having a hard time executing on its plan.

Clovis’ bid to move Rubraca into earlier ovarian cancer treatment continues to face pushback from drug regulators. As the company navigates a bankruptcy process, that regulatory scrutiny could negatively affect the company’s search for a buyer for the drug.